G De Meerleer
Overview
Explore the profile of G De Meerleer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muneer A, Bandini M, Comperat E, De Meerleer G, Fizazi K, Gietema J, et al.
ESMO Open
. 2024 Aug;
9(7):103481.
PMID: 39089768
No abstract available.
2.
Fonteyne V, Berghen C, Van Praet C, Vanderstraeten B, Verbeke S, Villeirs G, et al.
Radiother Oncol
. 2024 Jan;
193:110089.
PMID: 38278333
Background And Purpose: Moderate hypofractionated radiotherapy (HFRT) is a standard treatment for prostate cancer patients. We compared 2 moderate HFRT regimens, with a biologically equivalent dose of 80 Gy in...
3.
Deleu A, Ahmadi Bidakhvidi N, Van Wynsberge L, Van Laere K, De Meerleer G, Goffin K
Eur J Nucl Med Mol Imaging
. 2022 May;
49(11):3950-3951.
PMID: 35507060
No abstract available.
4.
Fonteyne V, Dirix P, Van Praet C, Berghen C, Albersen M, Junius S, et al.
Eur Urol Focus
. 2021 Dec;
8(5):1238-1245.
PMID: 34893458
Background: High-risk muscle-invasive bladder cancer (MIBC) has a poor prognosis. Old trials showed that external beam radiotherapy (EBRT) after radical cystectomy (RC) decreases the incidence of local recurrences but induces...
5.
Rans K, Berghen C, Joniau S, De Meerleer G
Clin Oncol (R Coll Radiol)
. 2020 Feb;
32(3):156-162.
PMID: 32035581
For patients experiencing biochemical recurrence in the absence of distant metastasis, salvage radiotherapy (SRT) with or without androgen deprivation therapy (ADT) is currently the only possible curative treatment option. Prostate-specific...
6.
Tosco L, Laenen A, Briganti A, Gontero P, Karnes R, Albersen M, et al.
Prostate Cancer Prostatic Dis
. 2017 May;
20(4):407-412.
PMID: 28485390
Background: Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk...
7.
Ost P, Jereczek-Fossa B, van As N, Zilli T, Tree A, Henderson D, et al.
Clin Oncol (R Coll Radiol)
. 2016 May;
28(9):e115-20.
PMID: 27133946
Aims: To report the relapse pattern of stereotactic body radiotherapy (SBRT) for oligorecurrent nodal prostate cancer (PCa). Materials And Methods: PCa patients with ≤3 lymph nodes (N1/M1a) at the time...
8.
Devos J, Van Praet C, Decaestecker K, Claeys T, Fonteyne V, Decalf V, et al.
Acta Clin Belg
. 2015 Mar;
70(4):272-9.
PMID: 25816107
Background: Men diagnosed with localised prostate cancer have to make a well-informed treatment choice between (robot-assisted) radical prostatectomy, external beam radiotherapy and, in selected cases, brachytherapy and active surveillance. We...
9.
Berkovic P, Van De Voorde L, De Meerleer G, Delrue L, Speleers B, Van Belle S, et al.
Strahlenther Onkol
. 2013 Dec;
190(2):223-8.
PMID: 24306063
Background: Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by mucinous peritoneal disease arising from disseminated peritoneal adenomucinosis. Primary treatment involves a combination of cytoreductive surgery with hyperthermic intraperitoneal...
10.
Lumen N, Fonteyne V, De Meerleer G, De Visschere P, Ost P, Oosterlinck W, et al.
Acta Clin Belg
. 2012 Oct;
67(4):270-5.
PMID: 23019802
Screening for prostate cancer has become a main controversial topic. First the currently used screening tools, PSA (Prostate Specific Antigen) and DRE (Digital Rectal Examination) have a low accuracy in...